Therapeutic Area: Oncology | Chiltern

Posted: September 3, 2017 at 6:45 am

Chiltern has conducted a wide variety of feasibility, pivotal and observational medical device, diagnostics and drug-device combination studies in oncology. Our device experience has included investigative sites in every geographic region of the world, including North America, Europe, Middle East, Africa, Latin America and Asia-Pacific. We have significant expertise in complying with country-specific ethics and regulatory requirements for specialized oncology devices (e.g., radioactive) to ensure timely approvals.

Through broad experience, Chiltern offers the skills and knowledge to start complex oncology trials quickly and proficiently. We have specific expertise in supporting adaptive design trials and the transition from feasibility to later phase clinical development. Our capabilities and global footprint will accelerate your oncology device from first-in-human studies to larger pivotal global trials.

Our experience conductingin vitrodiagnostics studies spans three decades. Chiltern continues to support complex diagnostics studies, mainly for premarket submission. We have supported studies in Asia-Pacific, Australia, Africa, North America and Western Europe with specific experience with breast cancer, chronic myelogenous leukemia, non-small cell lung cancer and systemic lupus erythematosus.

See more here:
Therapeutic Area: Oncology | Chiltern

Related Post